Cargando…

2134. Impact of ADC ß-lactamase amino acid variation on cefiderocol (FDC) susceptibility in carbapenem-resistant Acinetobacter baumannii (CRAb) strains

BACKGROUND: Infections due to CRAb cause high mortality in hospitalized patients. Treatment options are limited, but now include FDC, a novel siderophore cephalosporin. Following clinical implementation, cases of treatment-emergent resistance have been reported. Proposed resistance mechanisms includ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iovleva, Alina, McElheny, Christi, Kline, Ellen G, Bonomo, Robert A, Smoke, Steven, Falcone, Marco, Shields, Ryan K, Doi, Yohei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677112/ http://dx.doi.org/10.1093/ofid/ofad500.1757

Ejemplares similares

In Vitro Evolution of Cefiderocol Resistance in an NDM-Producing Klebsiella pneumoniae Due to Functional Loss of CirA
por: McElheny, Christi L., et al.
Publicado: (2021)

636. Genome Epidemiology of Carbapenem-Resistant Acinetobacter baumannii (CRAb) in the United States
por: Iovleva, Alina, et al.
Publicado: (2019)

Induced Heteroresistance in Carbapenem-Resistant Acinetobacter baumannii (CRAB) via Exposure to Human Pleural Fluid (HPF) and Its Impact on Cefiderocol Susceptibility
por: Mezcord, Vyanka, et al.
Publicado: (2023)

Isolation and Characterization of Lytic Bacteriophages Targeting Diverse Enterobacter spp. Clinical Isolates
por: Finney, Amanda G., et al.
Publicado: (2022)

Acinetobacter baumannii and Cefiderocol, between Cidality and Adaptability
por: Stracquadanio, Stefano, et al.
Publicado: (2022)

KPC-3–Producing Serratia marcescens Outbreak between Acute and Long-Term Care Facilities, Florida, USA
por: Jimenez, Adriana, et al.
Publicado: (2020)

Characterization of KPC-82, a KPC-2 Variant Conferring Resistance to Ceftazidime-Avibactam in a Carbapenem-Nonsusceptible Clinical Isolate of Citrobacter koseri
por: Lebreton, Francois, et al.
Publicado: (2021)

2185. In vitro activity of aztreonam-avibactam (ATM-AVI), cefiderocol (FDC), and cefepime-taniborbactam (FEP-TAN) against multi-species, NDM-producing Enterobacterales causing a local outbreak
por: Kline, Ellen G, et al.
Publicado: (2023)

Acinetobacter baumannii response to cefiderocol challenge in human urine
por: Nishimura, Brent, et al.
Publicado: (2022)

485. Clinical and Molecular Epidemiology of Carbapenem Non-susceptible Citrobacter sp.
por: Babiker, Ahmed, et al.
Publicado: (2019)

Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections
por: Watkins, Richard R, et al.
Publicado: (2023)

The Iron Content of Human Serum Albumin Modulates the Susceptibility of Acinetobacter baumannii to Cefiderocol
por: Escalante, Jenny, et al.
Publicado: (2023)

IS26-mediated plasmid reshuffling results in convergence of toxin–antitoxin systems but loss of resistance genes in XDR Klebsiella pneumoniae from a chronic infection
por: Luo, Ting L., et al.
Publicado: (2022)

Education: An overview from the author of ‘Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients’
por: Falcone, Marco
Publicado: (2021)

Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infection
por: Mabayoje, Diana A, et al.
Publicado: (2021)

Human Serum Proteins and Susceptibility of Acinetobacter baumannii to Cefiderocol: Role of Iron Transport
por: Le, Casin, et al.
Publicado: (2022)

Genomic epidemiology and antibiotic susceptibility profiling of uropathogenic Escherichia coli among children in the United States
por: Salamzade, Rauf, et al.
Publicado: (2023)

Case Report: Successful Rescue Therapy of Extensively Drug-Resistant Acinetobacter baumannii Osteomyelitis With Cefiderocol
por: Dagher, Michael, et al.
Publicado: (2020)

Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens
por: Bonomo, Robert A
Publicado: (2019)

Rapid detection of cefiderocol susceptibility/resistance in Acinetobacter baumannii
por: Raro, Otávio Hallal Ferreira, et al.
Publicado: (2023)

Biochemical and Structural Analysis of Inhibitors Targeting the ADC-7 Cephalosporinase of Acinetobacter baumannii
por: Powers, Rachel A., et al.
Publicado: (2014)

Clinical and Genomic Epidemiology of Carbapenem-Nonsusceptible Citrobacter spp. at a Tertiary Health Care Center over 2 Decades
por: Babiker, Ahmed, et al.
Publicado: (2020)

2759. Cefiderocol vs Best Available Therapy for the Treatment of Carbapenem- Resistant Acinetobacter baumannii
por: Daisey, Gabrielle N, et al.
Publicado: (2023)

Draft Genome Sequences of bla(KPC)-Containing Enterobacter aerogenes, Citrobacter freundii, and Citrobacter koseri Strains
por: Hazen, Tracy H., et al.
Publicado: (2018)

Genome dynamics of multidrug-resistant Acinetobacter baumannii during infection and treatment
por: Wright, Meredith S., et al.
Publicado: (2016)

1247. Molecular Epidemiology of Multi-drug Resistant Klebsiella pneumoniae and K. quasipneumoniae in Qatar
por: Tsui, Clement, et al.
Publicado: (2021)

Fosfomycin Resistance in Escherichia coli, Pennsylvania, USA
por: Alrowais, Hind, et al.
Publicado: (2015)

2134: Integrating Epidemiology and Biostatistics teaching using the case method
por: Paulus, Jessica K., et al.
Publicado: (2018)

In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel β-lactam/β-lactamase inhibitors
por: Shields, Ryan K, et al.
Publicado: (2023)

Cefiderocol for Severe Carbapenem-Resistant A. baumannii Pneumonia: Towards the Comprehension of Its Place in Therapy
por: Rando, Emanuele, et al.
Publicado: (2021)

In Vitro Activity of Cefiderocol against a Global Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates
por: Seifert, Harald, et al.
Publicado: (2023)

Collateral Changes in Cell Physiology Associated with ADC-7 β-Lactamase Expression in Acinetobacter baumannii
por: Colquhoun, Jennifer M., et al.
Publicado: (2023)

Diversity among bla(KPC)-containing plasmids in Escherichia coli and other bacterial species isolated from the same patients
por: Hazen, Tracy H., et al.
Publicado: (2018)

Effectiveness of RHZE-FDC (fixed-dose combination) compared to RH-FDC + Z for tuberculosis treatment in Brazil: a cohort study
por: Braga, José Ueleres, et al.
Publicado: (2015)

609. In vivo efficacy of human simulated exposures of cefiderocol (FDC) in combination with ceftazidime/avibactam (CZA) or meropenem (MEM) using in a 72 hour murine thigh infection model
por: Gill, Christian M, et al.
Publicado: (2022)

337 Nosocomial Transmission of Carbapenem-Resistant Acinetobacter baumannii (CRAb) among ICU Patients Detected by CRAb-LAMP
por: Yamamoto, Norihisa, et al.
Publicado: (2014)

1291. PROVE (Retrospective Cefiderocol Chart Review) Study of Real-World Outcomes and Safety in the Treatment of Patients with Gram-negative Bacterial Infections in the US and Europe
por: Marcella, Stephen, et al.
Publicado: (2021)

In vitro Activity of Cefiderocol Against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: a Single Center Experience
por: Quirino, Angela, et al.
Publicado: (2023)

Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance
por: Iovleva, Alina, et al.
Publicado: (2022)

Is It Possible to Eradicate Carbapenem-Resistant Acinetobacter baumannii (CRAB) from Endemic Hospitals?
por: Medioli, Filippo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_btg91n90tgismhvhkqkofuacnd